Not Tagged
Not Tagged
['cll', 'leukemia']
chronic lymphocytic leukemia research at #ash22: dana-farber's matthew davids, md ( ), details a study in high-risk #cll that found a triplet regimen avo was highly effective, with an 86% rate of undetectable minimal residual disease 
Dana-Farber Cancer Institute - a leading center for expert, compassionate cancer care and advanced research.
Appts: 877-442-3324 | https://t.co/HvCwkLltic